Navigation Links
CardioDx Announces Appointment of Dr. Louis G. Lange as Chairman of the Board of Directors
Date:10/8/2009

PALO ALTO, Calif., Oct. 8 /PRNewswire/ -- CardioDx, a cardiovascular genomic diagnostics company, announced today the appointment of Louis G. Lange, M.D., Ph.D., as Chairman of the company's Board of Directors. CardioDx recently launched Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(1) coronary artery disease (CAD) in patients with stable chest pain.

"Dr. Lange brings an ideal perspective to CardioDx as both a cardiologist and businessman who co-founded and cultivated a successful cardiovascular business," said David Levison, chief executive officer of CardioDx. "His clinical cardiology expertise, commercialization experience and firsthand understanding of diagnostics will serve as a great resource for the company as more physicians integrate Corus CAD into their daily practice."

Dr. Lange has over 20 years' experience in medicine at Harvard University and Washington University, where he served as Chief of Cardiology and Professor of Medicine at Jewish Hospital and was one of the first academicians in molecular cardiology. Most recently, Dr. Lange founded CV Therapeutics, Inc., where he served as Chairman and CEO from 1992 to 2009, overseeing the successful commercialization of a product portfolio solely focused on cardiovascular health. Dr. Lange led the company's success through its sale in 2009 to Gilead for $1.4B. Dr. Lange also sits on the boards of Maxygen, Metabolex and Synecor.

"I'm excited to join the Board of Directors of CardioDx as Chairman to help broaden adoption of Corus CAD, a groundbreaking blood-based test that helps office-based physicians more effectively assess obstructive CAD before more invasive testing may be necessary," said Dr. Lange. "I believe that Corus CAD signals the emergence of a new era in convenient and safe cardiovascular genomic diagnostics and will be of great use to all physicians who see chest pain patients on a daily basis."


'/>"/>
SOURCE CardioDx
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. IridoTech Announces IridoLab Self Service Kiosk
2. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
3. NCIIA Announces New Undergraduate Competition
4. Sangamo Announces Pricing of Public Offering of Common Stock
5. Varian, Inc. Announces Stockholder Approval of Merger Agreement With Agilent Technologies
6. Verenium Announces Proposed Public Offering of Common Stock
7. Boston Scientific Announces Exclusive Sponsorship and First Enrollments of MADIT-RIT Clinical Trial
8. YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
9. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
10. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
11. Vermillion Announces Return of Eric Fung, M.D., Ph.D.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...swire-FirstCall/ -- Dendreon Corporation (Nasdaq: ...g Administration (FDA) provided written acknowledg... Application (BLA) for PROVENGE® (sipuleucel-... Prescription Drug User Fee Act (PDUFA) date of Ma...on,s amended BLA. Dendreon is seeking licensure f...
(Date:11/20/2009)...OLEDO recently announced that a free webinar, &ldq...t-Line Particle Characterization”, will be p...e application of in situ particle characterization...ize a series of roller compaction runs while varyi...n forces. , (PRWEB) Novem...
(Date:11/19/2009)...wire-FirstCall/ -- Omeros Corporation (Nasdaq: OM...or the third quarter ended September 30, 2009. For... reported a net loss of $3.9 million, or $1.34 per... or $2.54 per share, for the same period in 2008. ...Company reported a net loss of $15.5 million, or $...
(Date:11/19/2009)...PRNewswire-FirstCall/ -- Spherix Incorporated (Nas...abetes therapy, and a provider of technical and re...biotechnology and pharmaceutical companies, today ...of Shareholders. ,, At the meeting, shareholder... the following members to the Board of Directors: ...
Breaking Biology Technology:Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3Roller Compaction Process Optimization Using At-Line Particle Characterization 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4
...uly 1 BioMarin,Pharmaceutical Inc. (Nasdaq and SW...h.D., Chief Medical Officer of BioMarin, will pres... Conference in New York City on,Wednesday, July 9,...cess a live audio webcast of the presentation,via ...p://www.BMRN.com . A,replay of the presentation wi...
... Ben Eynon Each Assume Vice President Roles at ...N, Texas, July 1 Molecular Imprints, Inc., the,ma...ms and solutions, today,announced that Ben Eynon a...These distinguished industry veterans are assuming...ness development for semiconductors, and,vice pres...
...lized Psychiatric Patient Evaluation for Clinical ...ug Development, HAMILTON, N.J., July 1 MedAvante...ent evaluation, announced today that it has,closed...nd Trevi Health,Ventures. MedAvante has developed ... the assessment of patients undergoing treatment i...
Other Biology Technology:BioMarin to Present at the Collins Stewart Growth Conference 2Industry Veterans Join Molecular Imprints' Management Team 2Industry Veterans Join Molecular Imprints' Management Team 3MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures 2MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures 3MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures 4
(Date:11/22/2009)...have succeeded in producing the polymers used for ...han through the use of fossil fuel based chemicals...w for the production of environmentally conscious ...l Biotechnology and Bioengineering to mark the j...ules found in everyday life in the form of plastic...
(Date:11/22/2009)...terfly,s proboscis looks like a straw -- long, sle...ke a paper towel, according to Konstantin Kornev o...s of this piece of insect anatomy to make small pr... Kornev will present his work next week at the 62...,s (APS) Division of Fluid Dynamics will take plac...
(Date:11/21/2009)...ewswire / - KINAXO Biotechnologies GmbH announce... new investors in the company, Leifina and Conmit ... Schumacher has been elected as a new member of th... Axel Ullrich, Hellmut Kirchner, Manfred Ferber as...tain Partners, BioM, High-Tech Grnderfonds, the Ma...
Breaking Biology News(10 mins):Bioengineers succeed in producing plastic without the use of fossil fuels 2KINAXO Completes Financing Round to Enhance Biomarker Development 2KINAXO Completes Financing Round to Enhance Biomarker Development 3WHO Withdraws Notice of Concern for Mylans Matrix Unit 13730 1NTU and Temasek Foundation transfer technology knowhow to Chinas quake prone regions 9723 1NTU and Temasek Foundation transfer technology knowhow to Chinas quake prone regions 9723 2NTU and Temasek Foundation transfer technology knowhow to Chinas quake prone regions 9723 3Kristi Yamaguchi Olympic Ice Skater Pushes Seasonal Flu Shots 55601 1Kristi Yamaguchi Olympic Ice Skater Pushes Seasonal Flu Shots 55601 2Kristi Yamaguchi Olympic Ice Skater Pushes Seasonal Flu Shots 55601 3
...DGE, Mass.-MIT scientists have found a way to indu...t could one day serve as tiny engineered blood ves...ol the cells, development by growing them on a sur...rk was posted this month in an online issue of Adv...d one day be transplanted into tissues such as the...
...ON, Ill. --- Neurotransmitters have consequences. ...y life, giving us the ability to move, to talk, to...ters are getting it right and sending proper signa...lls. , Now a Northwestern University study repor...controls a neurotransmitter in the nematode C. ele...
...ILLE, Tenn. U.S. Courts have decreed that the fe...naging nuclear wastes that will ensure the safety ...s, a period that is 200 times the length of record...rtainty in Long-Term Planning Nuclear Waste Manag...om government, industry, academia and the environm...
Other Biology News:MIT works toward engineered blood vessels 2Overexcited neurons not good for cell health 2Overexcited neurons not good for cell health 3Managing nuclear wastes for the millennia 2
VACUGENE PUMP 110V from GE Healthcare, formerly Amersham Biosciences
Rabbit Anti-DLK1 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Cryopreservation Service from AbD Serotec
...mismatch repair minus strains of E. coli. Use of t...zed unmethylated strand (1), leading to high mutat...ystems as the GeneEditor and Altered Sites II Muta...e recA+, therefore inserts containing highly repet...
Biology Products: